InSilico Medicine
InSilico Medicine is a clinical-stage biotechnology company that applies generative AI to drug discovery through its Pharma.AI platform.
Secondary Market Price
How InSilico Medicine Measures Up
To help you manage your InSilico Medicine equity, Prospect has run the company through our machine learning model.
Prospect Rating
--
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
Series E
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of InSilico Medicine's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future InSilico Medicine Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for InSilico Medicine's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Insilico Medicine is a clinical-stage biotechnology company that utilizes generative artificial intelligence for drug discovery and development. The company's current activities center on its AI-driven platforms—including PandaOmics for target discovery, Chemistry42 for designing novel molecular structures, and inClinico for forecasting clinical trial outcomes. These systems are used to develop treatments for cancer, fibrosis, central nervous system diseases, and autoimmune disorders. Founded in 2014 by Alex Zhavoronkov, the company has grown to over 200 employees with offices in Boston, New York, and Hong Kong. To date, Insilico Medicine has raised $306.3 million in total funding.
The company is currently advancing its drug pipeline, with a notable recent announcement being the first patient dosing in a Phase II trial for Garutadustat (ISM5411), a potential treatment for inflammatory bowel disease (IBD). This milestone followed the completion of two Phase I studies for the drug in Australia and China. In addition to its pharmaceutical development, Insilico continues to refine its technology platforms. The company recently collaborated with Microsoft to release an open-source version of its AI-powered scientific writing assistant, DORA (Document Oriented Research Assistant), and launched an updated version of its Alchemistry engine within the Chemistry42 platform, which reportedly improves the speed and accuracy of protein-ligand system analysis.
- Warburg Pincus
- Qiming Venture Partners
- B Capital Group
- Prosperity7 Ventures
- OrbiMed
- Deerfield Management
- Pavilion Capital
- CPE Fund
- Mirae Asset Capital
- Lilly Asia Ventures
- Eight Roads Ventures
- Lake Bleu Capital
- Baidu Ventures
- Sinovation Ventures
- Sequoia Capital China
- Hillhouse
- WuXi AppTec
- Value Partners Group
- Co-Founder, Alex Zhavoronkov
- Co-Founder, Alex Aliper
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is InSilico Medicine worth joining?
Deciding whether to join a company like InSilico Medicine involves evaluating its growth potential, company culture, and your personal career goals. A significant part of your compensation may be equity, and understanding its potential value is crucial for making an informed decision.
What should I do with my InSilico Medicine stock?
Managing your InSilico Medicine stock involves creating a strategy for exercising options, minimizing taxes, and deciding when to sell. Platforms like Prospect offer tools to help you develop a personalized plan and maximize the post-tax value of your equity.
Can you sell InSilico Medicine stock?
As a private company, selling InSilico Medicine stock is typically possible through secondary markets or company-approved tender offers, though it's less straightforward than selling public stock. Tools from platforms like Prospect can help you navigate these sales and identify tax-optimal shares to sell.
How can I find the value of my InSilico Medicine stock?
The value of private stock like InSilico Medicine's is often determined by the company's latest 409A valuation or recent funding rounds. For more advanced forecasting, Prospect provides predictive models and access to secondary market pricing data to help you estimate your equity's future worth.
What is InSilico Medicine's equity worth?
The total worth of InSilico Medicine's equity is based on its valuation, which is updated during funding rounds and through regular 409A valuations. To understand what your specific equity stake could be worth, you can use financial modeling tools to project future value based on various scenarios.
What is InSilico Medicine's stock ticker symbol?
InSilico Medicine is a private company and does not have a stock ticker symbol because its shares are not traded on a public stock exchange. Ticker symbols are assigned only when a company undergoes an Initial Public Offering (IPO).
Can I buy or sell InSilico Medicine stock?
Selling private InSilico Medicine stock is possible through secondary markets or tender offers, but buying it is generally restricted to accredited investors or employees receiving equity compensation. Platforms like Prospect provide tools to help employees manage and sell their existing shares tax-efficiently.
What is the criteria to buy or invest in InSilico Medicine stock?
Investing in a private company like InSilico Medicine is typically limited to institutional investors, venture capital firms, and accredited investors who meet specific SEC income or net worth requirements. Employees may also receive equity as part of their compensation package without needing to meet these criteria.
